Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer
Launched by UNIVERSITY OF ROCHESTER · Feb 28, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the effects of a seaweed supplement called fucoidan on cancer survivors who are experiencing fatigue and inflammation after their treatment. The study aims to see if taking fucoidan for eight weeks can help improve feelings of tiredness, weakness, and inflammation in these patients. The trial is not yet recruiting participants, but it plans to include adults aged 18 and older who have finished their cancer treatments, like surgery or chemotherapy, within the last ten years and who report feeling a certain level of fatigue.
To participate, individuals must be able to speak and understand English and be willing to take the fucoidan supplement regularly and attend study visits. However, those currently taking blood-thinning medications, using other fucoidan supplements, or with certain health issues, like major psychiatric illnesses or dementia, will not be eligible. Participants will need to complete some assessments to track their fatigue and overall health during the study. This trial is a great opportunity for cancer survivors looking for ways to feel better and manage their fatigue.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Survivors of cancer
- • Age 18 or older
- • Speak and understand English
- • Have completed surgery, radiation, and/or systemic intravenous anticancer therapy (e.g., chemotherapy, targeted therapy, immunotherapy) ≤10 years prior to enrollment.
- • Have a baseline level of fatigue, as determined by reporting a score of 4 or higher for the question, "In the last week, how bad was your worst fatigue on a scale from 0-10?"
- • Be willing to commit to the fucoidan supplement dosing and delivery method, to complete evaluation instruments, and to attend all study visits.
- • Completed Informed Consent
- Exclusion Criteria:
- • Current warfarin or other anti-coagulation medication use.
- • Current use of supplements that contain fucoidan
- • Any allergy to fucoidan
- • Be diagnosed with a major psychiatric illness requiring hospitalization within the last year.
- • Be diagnosed with dementia.
- • Be pregnant or nursing
About University Of Rochester
The University of Rochester is a leading academic institution dedicated to advancing medical research and improving patient care through innovative clinical trials. Renowned for its commitment to excellence in education, research, and clinical practice, the university fosters a collaborative environment that integrates cutting-edge scientific inquiry with practical applications in healthcare. With a focus on diverse therapeutic areas, the University of Rochester aims to enhance treatment options and outcomes for patients while contributing to the broader scientific community through rigorous study design and ethical standards in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported